Back to results
US 2026/0234726 A1Published application
Biomarker combinations for diagnosis of dilated cardiomyopathy and diagnostic kits therefor
OwnerYe Guinventor
Life of this patent
Estimating the term…
Abstract
This invention relates to a biomarker combination, diagnostic kits and methods for diagnosis of dilated cardiomyopathy, and use of the biomarker combination in preparation of the diagnostic kits for dilated cardiomyopathy. The biomarker combination comprises miR-126-5p and a tyrosine phosphorylation level of PECAM-1 proteins, wherein an expression level of miR-126-5p is upregulated in patients with dilated cardiomyopathy, and the tyrosine phosphorylation level of PECAM-1 protein is increased in the patients with the dilated cardiomyopathy.
Claims11
1-19. (canceled)
A diagnostic kit for detecting dilated cardiomyopathy, comprising:
- a cell isolation and extraction reagent comprising CD45-conjugated magnetic beads and CD31-conjugated magnetic beads configured to sequentially deplete CD45-positive leukocytes and capture CD31-positive endothelial cells from a peripheral blood sample;
- a first detection reagent comprising a primer pair designed for amplifying cDNA after reverse transcription of miR-126-5p, wherein the primer pair comprises a forward primer having the nucleotide sequence of SEQ ID NO:
- 3 and a reverse primer having the nucleotide sequence of SEQ ID NO:
- 4;
- and
- a second detection reagent comprising an anti-phosphotyrosine antibody reagent configured to detect tyrosine-phosphorylated PECAM-1 protein;
- wherein the cell isolation and extraction reagent, the first detection reagent, and the second detection reagent are adapted in a kit configuration to enable concurrent detection of miR-126-5p expression and PECAM-1 protein tyrosine phosphorylation in the captured endothelial cells.
4 more elements
Dependencies are inferred from the claim text.